Immunohistochemical Analysis of Expression, Phosphorylation, and Nuclear Translocation of NF-κB Proteins in Human Tissues

Vecchiotti, Davide; Verzella, Daniela; Capece, Daria; Cornice, Jessica; Nolfi, Mauro Di Vito; Francesco, Barbara Di; Franzoso, Guido; Alesse, Edoardo; Zazzeroni, Francesca

doi:10.1007/978-1-0716-1669-7_3

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemistry (IHC) was performed on tissue arrays from PCa (CA3, Su-perBioChips Tissue Array, Tema Ricerca, Italy) as previously described [35]. The primary antibodies used were as follows: anti-p65 (RB-1638-R7, ready to use, NeoMarker, Thermo Fisher Scientific, Fremont, CA, USA); anti-Shh (sc-1194 N19) (1:50, Santa Cruz Biotechnology); anti-GLI1 (sc-20687 H-300) (1:50, Santa Cruz Biotechnology, Dallas, Texas, USA).…”

Section: Immunohistochemistrymentioning

confidence: 99%

Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer

Vecchiotti

Verzella

Nolfi

et al. 2022

Cells

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most frequent cancer in men worldwide. NF-κB seems to play a key role in cell survival, proliferation and invasion, sustaining the heterogeneous multifocal nature of PCa. In recent years, the Hedgehog (Hh) signaling pathway has attracted attention as a therapeutic target due to its implication in tumorigenesis and metastasis in several types of cancer, including PCa. Although it is well-known that Sonic Hedgehog (SHh) is a transcriptional target of NF-κB(p65), and that GLI1 is the effector of this crosstalk, the precise role played by this axis in PCa is still not completely clear. Here, we set out to explore the correlation between NF-κB activation and SHh pathways in PCa, investigating if the interplay between NF-κB(p65) and SHh-GLI1 in advanced PCa could be a prospective therapeutic target. Our findings demonstrate that a NF-κB-SHh-GLI1 gene signature is enriched in PCa patients featuring a higher Gleason score. Moreover, elevated levels of this signature are associated with worse prognosis, thus suggesting that this axis could provide a route to treat aggressive PCa.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%